Comparative Pharmacology
Head-to-head clinical analysis: PROCALAMINE versus TRAVASOL 2 75 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCALAMINE versus TRAVASOL 2 75 IN DEXTROSE 25 IN PLASTIC CONTAINER.
PROCALAMINE vs TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
Travasol 2.75% in Dextrose 25% is a parenteral nutrition solution providing amino acids and carbohydrates. The amino acids serve as substrates for protein synthesis, while dextrose provides a source of calories and spares protein catabolism. It does not have a direct pharmacological target but supports metabolic functions.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
Intravenous administration only. Typical adult dose is 1 to 2 L per day, infused at a rate of 100 to 200 mL per hour, adjusted based on metabolic and fluid needs. Contains 2.75% amino acids and 25% dextrose.
None Documented
None Documented
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Not applicable as a single entity; amino acids have variable half-lives (minutes to hours), dextrose has a half-life of 1.5-2 hours in normoglycemic patients; clinical context: continuous infusion maintains steady state.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Renal: 100% as amino acids and dextrose metabolites; negligible biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution